At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 13 enrolled
Drug / intervention
cytisinedrug
Likely dose
cytisine 1.5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase 1 Open Label, Randomized, Two-Way Crossover Study in Healthy Smokers to Investigate the Effect of Food on the Bioavailability of Cytisine in a New Formulation
In Brief
A Phase 1 clinical trial evaluating cytisine for Smoking Cessation. Completed, enrolled 13 participants across 1 site.
Detailed Summary
This will be an open-label, randomised, 2-treatment period, single-dose crossover study to determine the comparative bioavailability and renal elimination following single-dose administration of 3.0 mg cytisine in healthy smokers under fed and fasted conditions.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmoking Cessation
CountriesUnited Kingdom
Collaborators--
Timeline
Phase 1CompletedFinished
20192020202120222023202420252026
First PostedApr 2018
Enrollment StartApr 2018
Primary CompletionJun 2018
Study CompletionJun 2018
TodayJul 2026
First PostedApr 27, 2018
Enrollment StartApr 27, 2018
Primary CompletionJun 10, 2018
Study CompletionJun 12, 2018
TodayJul 2, 2026
Enrollment to primary: 1 monthPosted 8.2 years ago
Interventions
cytisinedrug
cytisine 1.5 mg film-coated tablets